Physician profile
Patrick Dorvilus
NPI 1144222456
$4,609.27
in general payments reported to CMS, 2019-2025
28 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $729 · 2021: $278 · 2022: $577 · 2023: $472 · 2024: $640 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,294.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,456.65 | 2019-2025 | Linzess, Viberzi, Mavyret |
| Romark Laboratories, Lc | $540.03 | 2019-2020 | |
| Qol Medical, LLC | $496.47 | 2021-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $494.08 | 2022-2025 | Ibsrela |
| Boston Scientific Corporation | $202.24 | 2019-2023 | Orca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.89 | 2019-2024 | Trulance |
| Gilead Sciences, INC. | $175.80 | 2019-2025 | |
| Janssen Biotech, INC. | $142.57 | 2023-2025 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $111.31 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.04 | 2022 | |
| Aimmune Therapeutics, INC. | $104.27 | 2024-2025 | Zenpep |
| Pfizer INC. | $86.51 | 2020-2024 | |
| Madrigal Pharmaceuticals | $63.93 | 2025 | Rezdiffra |
| Allergan, INC. | $63.35 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.93 | 2019-2025 | Entyvio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $50.44 | 2020-2021 | |
| Exact Sciences Corporation | $33.99 | 2023-2024 | Cologuard Collection Kit |
| Organon LLC | $29.95 | 2025 | Renflexis, Hadlima |
| Ironwood Pharmaceuticals, INC | $25.13 | 2020 | |
| Pentax of America, INC. | $24.33 | 2020 | |
| Phathom Pharmaceuticals, INC. | $23.68 | 2025 | Voquezna |
| Vivus LLC | $22.31 | 2021 | |
| Conmed Corporation | $21.69 | 2025 | Conmed Generators |
| Ipsen Biopharmaceuticals, INC | $20.72 | 2025 | Iqirvo |
| Lilly USA, LLC | $20.69 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $16.58 | 2019 | |
| Celgene Corporation | $15.99 | 2024 | Zeposia |
| Medtronic, INC. | $14.70 | 2023 | Manoscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Dorvilus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.